myeloma

Pick anything below and it plays in the bar at the foot of the window — and keeps playing while you go on browsing the directory.

1. 1▶EHA2026 | DREAMM-8: Early RRMM and sustained MRD-negativity subgroup analysesMultiple Myeloma Hub5:20Notes
   +Listen later
2. 2▶EHA2026 | What are the latest findings from the phase I CaMMouflage trial evaluating CB-011 in RRMM?Multiple Myeloma Hub6:26Notes
   +Listen later
3. 3▶Strategies for managing belantamab mafodotin-associated ocular toxicitiesMultiple Myeloma Hub21:42Notes
   +Listen later
4. 4▶Integrating BCMA-directed bispecific antibodies into the treatment paradigm for MMMultiple Myeloma Hub20:21Notes
   +Listen later
5. 5▶EHA2026 | What are the updated 4-year results from the phase III DREAMM-7 trial in RRMM?Multiple Myeloma Hub5:51Notes
   +Listen later
6. 6▶What’s on the horizon for relapsed/refractory MM in 2026?Multiple Myeloma Hub5:36Notes
   +Listen later
7. 7▶CELMoDs for the treatment of newly diagnosed and HR smoldering MMMultiple Myeloma Hub6:29Notes
   +Listen later
8. 8▶CELMoDs for the treatment of relapsed/refractory MMMultiple Myeloma Hub18:25Notes
   +Listen later
9. 9▶CELMoDs: Mechanism of action and immunomodulatory activity in MMMultiple Myeloma Hub7:55Notes
   +Listen later
10. 10▶The patient experience: Treatment with BCMA-directed therapies in relapsed MMMultiple Myeloma Hub20:31Notes
    +Listen later